Assembly Biosciences is advancing a new class of oral therapeutics for the treatment of hepatitis B (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
- Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
Jun 22 - Jun 24, 2020
Jun 3, 2020 at 1:30 PM EDT
May 7, 2020 at 1:30 PM PDT